For CAR T therapy, Finney et al. determined that PD1 levels in patient apheresis product as well as PD1 acquisition during treatment were both predictive of a worse response for anti-CD19 CAR T for acute lymphoblastic leukemia (ALL) (37). Here, CD19 is linked to acute lymphoblastic leukemia.